Drug
BRAF V600E Inhibitor HLX208 clinical trials
Also written HLX208.
- studies test it
- 12
- open now
- 3
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the BRAF V600E Inhibitor HLX208 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BRAF V600E Inhibitor HLX208 is read from its arms, and is right about nine times in ten.
Testing it · 12
- HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid TumorsRecruitingPhase 1Shanghai Henlius BiotechNCT04965220Written as HLX 208
- A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationRecruitingPhase 1/2Shanghai Henlius BiotechNCT05641493Written as HLX208+HLX10
- A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationNot yet recruitingPhase 2Shanghai Henlius BiotechNCT05528406Written as HLX208
- Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy SubjectsCompletedPhase 1Shanghai Henlius BiotechNCT05902728Written as HLX208
- Mass Balance Study of [14C]HLX208 in China Healthy SubjectsCompletedPhase 1Shanghai Henlius BiotechNCT05841940Written as [14C]HLX208
- The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationActive, not recruitingPhase 1/2Shanghai Henlius BiotechNCT05102292Written as HLX208
- The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line TreatmentActive, not recruitingPhase 2Shanghai Henlius BiotechNCT04984369Written as HLX208
- The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationActive, not recruitingPhase 2Shanghai Henlius BiotechNCT05127759Written as HLX208
- The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E MutationActive, not recruitingPhase 2Shanghai Henlius BiotechNCT05092815Written as HLX208
- The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line TreatmentStatus unknownPhase 2Shanghai Henlius BiotechNCT05092802Written as HLX208
- A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 MutationStatus unknownPhase 2Shanghai Henlius BiotechNCT05114603Written as HLX208
- A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 MutationStatus unknownPhase 2Shanghai Henlius BiotechNCT05065398Written as HLX208